Baird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) saying they are incrementally negative following 4Q14 earnings call.Skorney ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE